EGFR and cancer: Recently, Vandetanib(Zactima; ZD6474), an oral small-molecule multitargeted tyrosine kinase inhibitors (TKIs) that primarily targets vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase activity, has been revealed to exhibit anti-angiogenic and anti-proliferative effects in a panel of histologically diverse human cancer xenografts in nude mice, including NPC8, 9, 10, 11, 12.